NCT05555589 · Interventional trial
Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2
Overall registry status Completed
Phase 3
Conditions Neurotrophic Keratopathy
Delaware Valley sites
- Scheie Eye Institute, University of Pennsylvania · Philadelphia, PA · Philadelphia County
First posted
Registry updated
Added to the directory